logo-loader
viewAdamas Finance Asia Limited

Adamas Finance Asia to invest in developer of needle-free injection technology

Suresh Withana from Harmony Capital, the investment manager of Adamas Finance Asia Limited (LON:ADAM), tells Proactive London's Andrew Scott they're planning to invest up to US$5mln into the developer of needle-free injection technology.

PharmaJet Inc’s innovative technology has received US Food & Drug Administration marketing clearance, is CE-Marked in Europe and is PQS certified by the World Health Organisation.

Quick facts: Adamas Finance Asia Limited

Price: 27.5 GBX

AIM:ADAM
Market: AIM
Market Cap: £24.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Adamas Finance Asia Limited named herein, including the promotion by the Company of Adamas Finance Asia Limited in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Adamas Finance Asia's Harmony Capital 'delivers' on promises...

Harmony Capital, of Adamas Finance Asia Limited (LON:ADAM) says market conditions for its largest investment, a quarry in China, are set for a strong period of growth following the asset going into production on December 27th. Managing Partner of the investment manager Suresh Withana tells...

on 8/1/20

2 min read